Under non-tumor purity conditions, the downregulation of KLRB1 expression was significantly associated with changes in the expression levels of immune cell markers such as CD8A, CD8B, CD3D, CD3E, CD2, CD19, CD79A, CD86, PDCD1, CTLA4, LAG3, HAVCR2, GZMB, CSF1R, CCL2, CD68, IL10, NOS2, IRF5, PTGS2, CD163, VSIG4, MS4A4A, CEACAM8, ITGAM, CCR7, KIR2DL1, KIR2DL3, KIR2DL4, KIR3DL1, KIR3DL2, KIR3DL3, KIR2DS4, HLA-DPB1, HLA-DQB1, HLA-DRA, HLA-DPA1, CD1C, ITGAX, TBX21, STAT4, STAT1, IFNG, TNF, GATA3, STAT6, STAT5A, IL13, IL21, IL17A, FOXP3, CCR8, STAT5B, and TGFB1 (Table 3 and Fig. 13). The gene discussed is IL17A; the disease is neoplasm.